Christopher Silber

985 total citations · 1 hit paper
26 papers, 726 citations indexed

About

Christopher Silber is a scholar working on Psychiatry and Mental health, Biological Psychiatry and Behavioral Neuroscience. According to data from OpenAlex, Christopher Silber has authored 26 papers receiving a total of 726 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Psychiatry and Mental health, 6 papers in Biological Psychiatry and 4 papers in Behavioral Neuroscience. Recurrent topics in Christopher Silber's work include Tryptophan and brain disorders (6 papers), Stress Responses and Cortisol (4 papers) and Epilepsy research and treatment (4 papers). Christopher Silber is often cited by papers focused on Tryptophan and brain disorders (6 papers), Stress Responses and Cortisol (4 papers) and Epilepsy research and treatment (4 papers). Christopher Silber collaborates with scholars based in United States and United Kingdom. Christopher Silber's co-authors include Stephen Kanes, James Doherty, Alan M. Rapoport, Laura I. Rankin, N. T. Mathew, Stephen D. Silberstein, Seymour Solomon, Herbert G. Markley, Roger Deaton and Joel R. Saper and has published in prestigious journals such as New England Journal of Medicine, Neurology and Biological Psychiatry.

In The Last Decade

Christopher Silber

26 papers receiving 682 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Zuranolone vs Placebo in Postpartum Depression

2021 149 citations Kristina M. Deligiannidis, Samantha Meltzer‐Brody et al. JAMA Psychiatry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Silber United States	9	369	156	154	136	131	26	726
Jan Malte Bumb Germany	21	426 1.2×	386 2.5×	158 1.0×	113 0.8×	40 0.3×	51	1.1k
Tatjana Dose Germany	7	174 0.5×	196 1.3×	177 1.1×	61 0.4×	32 0.2×	10	658
Çiğdem Aydemir Türkiye	10	112 0.3×	54 0.3×	247 1.6×	43 0.3×	100 0.8×	25	573
Dorottya Pap Hungary	16	165 0.4×	91 0.6×	88 0.6×	72 0.5×	34 0.3×	34	623
Xiaoe Lang China	16	306 0.8×	122 0.8×	275 1.8×	114 0.8×	29 0.2×	60	780
M. Kâzım Yazıcı Türkiye	19	710 1.9×	147 0.9×	56 0.4×	58 0.4×	38 0.3×	43	1.1k
C R Lake United States	14	189 0.5×	99 0.6×	85 0.6×	131 1.0×	34 0.3×	30	905
Johan Beck-Friis Sweden	13	157 0.4×	76 0.5×	196 1.3×	151 1.1×	21 0.2×	20	903
Dong-Bin Cai China	21	443 1.2×	228 1.5×	308 2.0×	69 0.5×	11 0.1×	43	988
Nikita N. Burke Ireland	14	99 0.3×	209 1.3×	167 1.1×	304 2.2×	21 0.2×	25	854

Countries citing papers authored by Christopher Silber

Since Specialization

Citations

This map shows the geographic impact of Christopher Silber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Silber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Silber more than expected).

Fields of papers citing papers by Christopher Silber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Silber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Silber. The network helps show where Christopher Silber may publish in the future.

Co-authorship network of co-authors of Christopher Silber

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Silber. A scholar is included among the top collaborators of Christopher Silber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Silber. Christopher Silber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Suthoff, Ellison, Mark Kosinski, Paul Hodgkins, et al.. (2022). Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder. Journal of Affective Disorders. 308. 19–26. 19 indexed citations

Deligiannidis, Kristina M., Samantha Meltzer‐Brody, Handan Gunduz‐Bruce, et al.. (2021). Effect of Zuranolone vs Placebo in Postpartum Depression. JAMA Psychiatry. 78(9). 951–951. 149 indexed citations breakdown →

Bullock, Amy, Handan Gunduz‐Bruce, Gary Zammit, et al.. (2021). A phase 1 double‐blind, placebo‐controlled study of zuranolone (SAGE‐217) in a phase advance model of insomnia in healthy adults. Human Psychopharmacology Clinical and Experimental. 37(1). e2806–e2806. 15 indexed citations

Bullock, Amy, Inder Kaul, Sigui Li, et al.. (2020). Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study. Journal of the Neurological Sciences. 421. 117277–117277. 19 indexed citations

Clayton, Anita H., Robert Lasser, Indrani Nandy, et al.. (2020). SAGE-217 in Major Depressive Disorder: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial (705). Neurology. 94(15_supplement). 1 indexed citations

Werneburg, Brian, Anita H. Clayton, Robert Lasser, et al.. (2020). P.305 The GABAA receptor positive allosteric modulator zuranolone in major depressive disorder: a double-blind, randomized, placebo-controlled phase 3 trial. European Neuropsychopharmacology. 40. S176–S177. 1 indexed citations

Clayton, Anita H., Robert Lasser, Indrani Nandy, et al.. (2020). A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Patients With Major Depressive Disorder. Biological Psychiatry. 87(9). S86–S86. 4 indexed citations

Gunduz-Bruce, Handan, Christopher Silber, Inder Kaul, et al.. (2019). Trial of SAGE-217 in Patients with Major Depressive Disorder. New England Journal of Medicine. 381(10). 903–911. 161 indexed citations

Bonthapally, Vijayveer, Handan Gunduz-Bruce, Christopher Silber, et al.. (2019). Health-related quality of life in a Phase 2, randomized, placebo-controlled trial of the GABA(A)R modulator SAGE-217 in major depressive disorder. European Neuropsychopharmacology. 29. S58–S58. 1 indexed citations

10.

Gunduz-Bruce, Handan, Christopher Silber, Anthony J. Rothschild, et al.. (2019). SAGE-217 in major depressive disorder: A multicenter, randomized, double-blind, Phase 2 placebo-controlled trial. European Neuropsychopharmacology. 29. S59–S60. 3 indexed citations

11.

Bonthapally, Vijayveer, Ellison Suthoff, P. Hodgkins, et al.. (2018). PMH76 - PATIENT REPORTED MEASURES OF DEPRESSIVE SYMPTOMS AND FATIGUE IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER. Value in Health. 21. S287–S287. 1 indexed citations

12.

Gunduz-Bruce, Handan, Christopher Silber, Anthony J. Rothschild, et al.. (2018). O46. SAGE-217 a First in Class GABAA Receptor Positive Allosteric Modulator in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Phase 2 Placebo-Controlled Trial. Biological Psychiatry. 83(9). S127–S128. 1 indexed citations

13.

Tamminga, Carol A., Randall J. Mack, G. Richard Granneman, Christopher Silber, & Kenneth B. Kashkin. (1997). Sertindole in the treatment of psychosis in schizophrenia. International Clinical Psychopharmacology. 12. S29–S36. 32 indexed citations

14.

Buckley, Peter F., et al.. (1997). The safety and tolerability of sertindole in elderly patients with dementia. Schizophrenia Research. 24(1-2). 201–201. 2 indexed citations

15.

Lahti, Adrienne C., Christopher Silber, & Randall J. Mack. (1997). The action of sertindole on negative symptoms in schizophrenia. Schizophrenia Research. 24(1-2). 202–202. 1 indexed citations

16.

Thal, L. J., Angelico Carta, Rachelle S. Doody, et al.. (1997). Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.. PubMed. 11 Suppl 3. 46–9. 25 indexed citations

17.

Mack, Randall J., Richard Driscoll, & Christopher Silber. (1997). P.2.042 The long term cardiovascular safety of sertindole. European Neuropsychopharmacology. 7. S207–S207. 4 indexed citations

18.

Ereshefsky, Larry, Azmi Nabulsi, Christopher Silber, & Randall J. Mack. (1997). Reduction of hospital days in sertindole treated patients: One year findings. Schizophrenia Research. 24(1-2). 201–202. 2 indexed citations

19.

Foley, Sharon, et al.. (1997). P.2.023 A multi-center, one year, haloperidol controlled trial assessing the long term safety, efficacy and quality of life of sertindole in stable schizophrenic patients. European Neuropsychopharmacology. 7. S201–S202. 1 indexed citations

20.

Mathew, N. T., Joel R. Saper, Stephen D. Silberstein, et al.. (1995). Migraine Prophylaxis With Divalproex. Archives of Neurology. 52(3). 281–286. 261 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact